No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Shenzhen Weiguang Biological Products Co., Ltd. is a Chinese enterprise primarily dedicated to the entire lifecycle of blood products, encompassing their research, development, manufacturing, and distribution within the domestic market. Its comprehensive portfolio features a range of crucial blood-derived therapies, including human albumin, various intravenous immunoglobulin preparations (such as pH4 and its freeze-dried counterpart), general human immunoglobulin, and specific immunoglobulins targeting conditions like hepatitis B, rabies, and tetanus. Additionally, it provides histamine human immunoglobulin and human fibrinogen. These offerings collectively represent nine distinct product types, available in twenty-one different specifications. Established in 1985, the firm maintains its headquarters in Shenzhen, China.
www.szwg.comNo one on the platform currently holds 002880.SZ.
No tracked institution reports a position in 002880.SZ as of their last filing.
No one on the platform has traded 002880.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.7% | — | — | — | ||
| Rev. Growth % | 5.3% | 7.0% | ||||
| Profit Margin % | 19.4% | 20.3% | 21.8% | |||
| Free Cash Flow Margin % | 7.4% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.3B | +15.0% | $0.97 | $0.97–$0.97 | — | 1 |
| 2027 | $1.4B | +8.1% | $1.10 | $1.10–$1.10 | — | 1 |
| 2028 | $1.5B | +6.5% | $1.22 | $1.22–$1.22 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002880.SZShenzhen Weiguang Biological Products Co., Ltd. | $20.26 | +0.30% | $4.6B | — |
| 000078.SZShenzhen Neptunus Bioengineering Co., Ltd. | $1.50 | +0.00% | $3.9B | — |
| 002349.SZJinghua Pharmaceutical Group Co., Ltd. | $8.02 | -2.08% | $6.7B | — |
| 002370.SZZhejiang Yatai Pharmaceutical Co., Ltd. | $5.13 | +0.79% | $3.8B | — |
| 002393.SZTianjin Lisheng Pharmaceutical Co.,Ltd. | $13.41 | -0.30% | $4.1B | — |
| 002793.SZLuoxin Pharmaceuticals Group Stock Co., Ltd. | $4.47 | +0.22% | $4.9B | — |
| 300039.SZShanghai Kaibao Pharmaceutical CO.,Ltd | $5.02 | -0.00% | $5.3B | — |
Source: Financial Modeling Prep · peers by sector/industry